FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

This story appears to have been written by the PR department of the company that makes Invega- the first once-monthly atypicle antipsychotic approved for Schizophrenia in the United States.

Link to full article

Submitted by: Darrell H.

Speak Your Mind